Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection

International Journal of Tuberculosis and Lung Disease

Volumn 21, Issue 9, 2017, Pages 965-976

  Zenner, D ^a,b,c   Hafezi, H ^a   Potter, J ^d   Capone, S ^e   Matteelli, A ^e  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Cost effectiveness; Effectiveness; LTBI screening; Public health impact; TB case finding

Indexed keywords

ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PLACEBO; RIFAMPICIN;

CLINICAL EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; HIGH RISK POPULATION; HUMAN; INCIDENCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; MATHEMATICAL MODEL; MIGRANT; MONOTHERAPY; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING; SENSITIVITY AND SPECIFICITY; SPUTUM CULTURE; SPUTUM SMEAR; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; ECONOMICS; MASS SCREENING; MIGRATION; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

COST-BENEFIT ANALYSIS; HUMANS; INCIDENCE; LATENT TUBERCULOSIS; MASS SCREENING; OBSERVATIONAL STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TRANSIENTS AND MIGRANTS; TUBERCULOSIS;

EID: 85018884305     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.16.0935     Document Type: Review

References (122)

1. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Lond Engl 2016; 388: 1459-1544.
2. World Health Organization. Global tuberculosis report, 2016. WHO/HTM/TB/2016.13. Geneva, Switzerland: WHO, 2016.
3. World Health Organization. The End TB Strategy. Geneva, Switzerland: WHO, 2015.
4. European Centre for Disease Prevention and Control. Tuberculosis surveillance and monitoring in Europe. Stockholm, Sweden: ECDC, 2016. http://ecdc.europa.eu/en/ publications/Publications/ecdc-tuberculosis-surveillancemonitoring- Europe-2016.pdf Accessed May 2017.
5. Lönnroth K, Mor Z, Erkens C, et al. Tuberculosis in migrants in low-incidence countries: epidemiology and intervention entry points. Int J Tuberc Lung Dis 2017; 21: 624-636.
6. Golub J E, Mohan C I, Comstock G W, Chaisson R E. Active case finding of tuberculosis: historical perspective and future prospects. Int J Tuberc Lung Dis 2005; 9: 1183-1203.
7. Abubakar I, Thomas H L, Morgan M, Anderson S, Zenner D, Cosford P. A collaborative strategy to tackle tuberculosis in England. Lancet 2015; 385: 312-313.
8. Zenner D, Zumla A, Gill P, Cosford P, Abubakar I. Reversing the tide of the UK tuberculosis epidemic. Lancet 2013; 382: 1311-1312.
9. Kranzer K, Afnan-Holmes H, Tomlin K, et al. The benefits to communities and individuals of screening for active tuberculosis disease: a systematic review. Int J Tuberc Lung Dis 2013; 17: 432-446.
10. Scottish Intercollegiate Guidelines Network (SIGN). A guideline developer's handbook (SIGN publication no. 50). Edinburgh, Scotland, UK: SIGN, 2015. http://www.sign.ac.uk Accessed May 2017.
11. Campbell J R, Krot J, Elwood K, Cook V, Marra F. A systematic review on TSTand IGRA tests used for diagnosis of LTBI in immigrants. Mol Diagn Ther 2015; 19: 9-24.
12. Arshad S, Bavan L, Gajari K, Paget S N, Baussano I. Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis. Eur Respir J 2010; 35: 1336-1345.
13. Trauer JM, Krause V L. Assessment and management of latent tuberculosis infection in a refugee population in the Northern Territory. Med J Aust 2011; 194: 579.
14. Mulder C, Mulleners B, BorgdorffMW, van Leth F. Predictive value of the tuberculin skin test among newly arriving immigrants. PLOS ONE 2013; 8: e60130.
15. Pareek M, Bond M, Shorey J, et al. Community-based evaluation of immigrant tuberculosis screening using interferon c release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013; 68: 230-239.
16. Carvalho A C C, Saleri N, El-Hamad I, et al. Completion of screening for latent tuberculosis infection among immigrants. Epidemiol Infect 2005; 133: 179-185.
17. Meier V, Artelt T, Cierpiol S, Gossner J, Scheithauer S. Tuberculosis in newly arrived asylum seekers: a prospective 12 month surveillance study at Friedland, Germany. Int J Hyg Environ Health 2016; 219: 811-815.
18. Pareek M, Watson J P, Ormerod L P, et al. Screening of immigrants in the UK for imported latent tuberculosis: a multicentre cohort study and cost-effectiveness analysis. Lancet Infect Dis 2011; 11: 435-444.
19. Bodenmann P, Vaucher P, Wolff H, et al. Screening for latent tuberculosis infection among undocumented immigrants in Swiss healthcare centres; a descriptive exploratory study. BMC Infect Dis 2009; 9: 1-8.
20. Bua A, Cubeddu M, Piras D, Delogu R, Zanetti S, Molicotti P. Tuberculosis screening among asylum seekers in Sardinia. J Public Health (Oxf) 2016; 38: 760-764.
21. Lucas M, Nicol P, McKinnon E, et al. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 2010; 65: 442-448.
22. Flynn M, Brown L, Tesfai A, Lauer T. Post-migration screening for active tuberculosis in Victoria, Australia. Int J Tuberc Lung Dis 2012; 16: 50-54.
23. Johnsen N L, Steen T W, Meyer H, Heldal E, Skarpaas I J K, June G B. Cohort analysis of asylum seekers in Oslo, Norway, 1987-1995: effectiveness of screening at entry and TB incidence in subsequent years. Int J Tuberc Lung Dis; 9: 37-42.
24. Khan K, Hirji M M, Miniota J, et al. Domestic impact of tuberculosis screening among new immigrants to Ontario, Canada. CMAJ 2015; 187: E473-481.
25. Liu Y, Weinberg M S, Ortega L S, Painter J A, Maloney S A. Overseas screening for tuberculosis in US-bound immigrants and refugees. N Engl J Med 2009; 360: 2406-2415.
26. Mathez C, Bangala Y, Bady P, Zellweger J P. Active screening for pulmonary tuberculosis among immigrants by chest X-ray at the Swiss border. Swiss Med Wkly 2007; 137: 649-654.
27. Brassard P, Steensma C, Cadieux L, Lands L C. Evaluation of a school-based tuberculosis-screening program and associate investigation targeting recently immigrated children in a lowburden country. Pediatrics 2006; 117: e148-156.
28. Chang S, Wheeler L S, Farrell K P. Public health impact of targeted tuberculosis screening in public schools. Am J Public Health 2002; 92: 1942-1945.
29. Baussano I, Mercadante S, Pareek M, Lalvani A, Bugiani M. High rates of Mycobacterium tuberculosis among socially marginalized immigrants in low-incidence area, 1991-2010, Italy. Emerg Infect Dis 2013; 19: 1437-1445.
30. Minodier P, Lamarre V, Carle M-E, Blais D, Ovetchkine P, Tapiero B. Evaluation of a school-based program for diagnosis and treatment of latent tuberculosis infection in immigrant children. J Infect Public Health 2010; 3: 67-75.
31. Levesque J, Dongier P, Brassard P, Allard R. Acceptance of screening and completion of treatment for latent tuberculosis infection among refugee claimants in Canada. Int J Tuberc Lung Dis 2004; 8: 711-717.
32. Li J, Munsiff S S, Agerton T B. Prevalence of tuberculin skin test positivity in clinical population in New York City. J Immigr Minor Health 2010; 12: 816-822.
33. Mulder C, van Deutekom H, Huisman E M, et al. Role of the QuantiFERONw-TB Gold In-Tube assay in screening new immigrants for tuberculosis infection. Eur Respir J 2012; 40: 1443-1449.
34. Harling R, Pearce M, Chandrakumar M, Mueller K, Hayward A. Tuberculosis screening of asylum seekers: 1 years' experience at the Dover Induction Centres. Public Health 11; 121: 822-827.
35. Lifson A R, Thai D, O'Fallon A, Mills W A, Hang K. Prevalence of tuberculosis, hepatitis B virus, and intestinal parasitic infections among refugees to Minnesota. Public Health Rep 2002; 117: 69-77.
36. Desale M, Bringardner P, Fitzgerald S, Page K, Shah M. Intensified case-finding for latent tuberculosis infection among the Baltimore city Hispanic population. J Immigr Minor Health 2013; 15: 680-685.
37. Mor Z, Lerman Y, Leventhal A. Pre-immigration screening process and pulmonary tuberculosis among Ethiopian migrants in Israel. Eur Respir J 2008; 32: 413-418.
38. Varkey P, Jerath A U, Bagniewski S M, Lesnick T G. The epidemiology of tuberculosis among primary refugee arrivals in Minnesota between 1997 and 2001. J Travel Med 2007; 14: 1-8.
39. Harstad I, Jacobsen G W, Heldal E, et al. The role of entry screening in case finding of tuberculosis among asylum seekers in Norway. BMC Public Health 2010; 10: 670.
40. Tafuri S, Martinelli D, Melpignano L, et al. Tuberculosis screening in migrant reception centers: results of a 2009 Italian survey. Am J Infect Control 2011; 39: 495-499.
41. King K, Douglas P J, Beath K. Is premigration health screening for tuberculosis worthwhile. Med J Aust 2011; 195: 534-537.
42. Maloney S A, Fielding K L, Laserson K F, et al. Assessing the performance of overseas tuberculosis screening programs: a study among us-bound immigrants in vietnam. Arch Intern Med 2006; 166: 234-240.
43. Mor Z, Leventhal A, Weiler-Ravell D, Peled N, Lerman Y. Chest radiography validity in screening pulmonary tuberculosis in immigrants from a high-burden country. Respir Care 2012; 57: 1137-1144.
44. Plant A J,Watkins R E,Motus N, et al. Results of tuberculosis screening in applicants for migration in Vietnam and Cambodia. Int J Tuberc Lung Dis 2005; 9: 157-163.
45. Aldridge R W, Zenner D, White P J, et al. Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK: a population-based cross-sectional study. Lancet Infect Dis 2016; 16: 962-970.
46. Liu Y, Posey D L, Cetron M S, Painter J A. Effect of a culturebased screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Ann Intern Med 2015; 162: 420-428.
47. Alvarez G G, Gushulak B, Rumman K A, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis 2011; 11: 1-12.
48. Losi M, Bergamini B, Venturelli C, et al. Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing [Short communication]. Int J Tuberc Lung Dis 2011; 15: 1182-1184.
49. Padovese V, Egidi A, Melillo T F, et al. Prevalence of latent tuberculosis, syphilis, hepatitis B and C among asylum seekers in Malta. J Public Health (Oxf) 2014; 36: 22-27.
50. Yanni E A, Naoum M, Odeh N, Han P, Coleman M, Burke H. The health profile and chronic diseases comorbidities of USbound Iraqi refugees screened by the International Organization for Migration in Jordan: 2007-2009. J Immigr Minor Health 2013; 15: 1-9.
51. Winje B A, Oftung F, Korsvold G E, et al. Screening for tuberculosis infection among newly arrived asylum seekers: comparison of QuantiFERONwTB Gold with tuberculin skin test. BMC Infect Dis 2008; 8: 1-10.
52. Hladun O, Grau A, Esteban E, Jansà J M. Results from screening immigrants of low-income countries: data from a public primary health care. J Travel Med. 2014; 21: 92-98.
53. Erkens C, Slump E, Kamphorst M, et al. Coverage and yield of entry and follow-up screening for tuberculosis among new immigrants. Eur Respir J 2008; 32: 153-161.
54. Dasgupta K, Schwartzman K, Marchand R, Tennenbaum TN, Brassard P, Menzies D. Comparison of cost-effectiveness of tuberculosis screening of close contacts and foreign-born populations. Am J Respir Crit Care Med 2000; 162: 2079-2086.
55. Hardy A B, Varma R, Collyns T, Moffitt S J, Mullarkey C, Watson J P. Cost-effectiveness of the NICE guidelines for screening for latent tuberculosis infection: the QuantiFERONTB Gold IGRA alone is more cost-effective for immigrants from high burden countries. Thorax 2010; 65: 178-180.
56. Khan K, Muennig P, Behta M, Zivin J G. Global drugresistance patterns and the management of latent tuberculosis infection in immigrants to the United States. N Engl J Med 2002; 347: 1850-1859.
57. Linas B P,Wong AY, Freedberg K A, Horsburgh C R. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
58. Haukaas F S, Arnesen T M, Winje B A, Aas E. Immigrant screening for latent tuberculosis in Norway: a costeffectiveness analysis. Eur J Health Econ 2017; 18: 405-415.
59. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TBscreening in high-income countries: a costeffectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
60. Porco T C, Lewis B, Marseille E, Grinsdale J, Flood J M, Royce S E. Cost-effectiveness of tuberculosis evaluation and treatment of newly-arrived immigrants. BMC Public Health 2006; 6: 1-15.
61. La'Marcus T W, Coleman M S, de la Motte Hurst C, et al. A cost-benefit analysis of a proposed overseas refugee latent tuberculosis infection screening and treatment program. BMC Public Health 2015; 15: 1.
62. Auguste P, Tsertsvadze A, Pink J, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technol Assess 2016; 20: 1-678.
63. Schwartzman K, Menzies D. Tuberculosis screening of immigrants to low-prevalence countries. Am J Respir Crit Care Med 2000; 161: 780-789.
64. Wingate LT, ColemanMS, PoseyD L, et al. Cost-effectiveness of screening and treating foreign-born students for tuberculosis before entering the United States. PLOS ONE 2015; 10: e0124116.
65. World Health Organization. WHO Expert Committee on Tuberculosis: ninth report.WHOTechnical Report Series, No. 552. Geneva, Switzerland: WHO, 1974. http://apps.who.int/ iris/bitstream/10665/41095/1/WHO-TRS-552-eng.pdf Accessed May 2017.
66. World Health Organization. Systematic screening for active tuberculosis Principles and recommendations. WHO/HTM/ TB/2013.04. Geneva, Switzerland: WHO, 2013. http://www. who.int/tb/publications/Final-TB-Screening-guidelines.pdf Accessed May 2017.
67. Lönnroth K, Migliori G B, Abubakar I, et al. Towards tuberculosis elimination: an action framework for lowincidence countries. Eur Respir J 2015; 45: 928-952.
68. Jit M, StaggHR, Aldridge RW, White P J, Abubakar I; For the Find and Treat Evaluation Team. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ 2011; 343: d5376.
69. Klinkenberg E, Manissero D, Semenza J C, Verver S. Migrant tuberculosis screening in the EU/EEA: yield, coverage and limitations. Eur Respir J 2009; 34: 1180-1189.
70. Alvarez G, Gushulak B, Rumman K, et al. A comparative examination of tuberculosis immigration medical screening programs from selected countries with high immigration and low tuberculosis incidence rates. BMC Infect Dis 2011; 11: 3.
71. Kunst H, Burman M, Arnesen T M, et al. Tuberculosis and latent tuberculosis infection screening in migrants in Europe: comparative analysis of policies, surveillance systems and results. Int J Tuberc Lung Dis 2017; 21: 840-851.
72. Aldridge R W, Yates T A, Zenner D, White P J, Abubakar I, Hayward A C. Pre-entry screening programmes for tuberculosis in migrants to low-incidence countries: a systematic review and meta-analysis. Lancet Infect Dis 2014; 14: 1240-1249.
73. Zenner D, Southern J, van Hest R, et al. Active case finding for tuberculosis among high-risk groups in low-incidence countries. Int J Tuberc Lung Dis 2013; 17: 573-582.
74. Van't Hoog AH, Onozaki I, Lönnroth K. Choosing algorithms for TB screening: a modelling study to compare yield, predictive value and diagnostic burden. BMC Infect Dis 2014; 14: 532.
75. den Boon S, White NW, van Lill SWP, et al. An evaluation of symptom and chest radiographic screening in tuberculosis prevalence surveys. Int J Tuberc Lung Dis 2006; 10: 876-882.
76. English R G, Bachmann M O, Bateman E D, et al. Diagnostic accuracy of an integrated respiratory guideline in identifying patients with respiratory symptoms requiring screening for pulmonary tuberculosis: a cross-sectional study. BMC Pulm Med 2006; 6: 22.
77. van't Hoog A H, Williamson J, Sewe M, et al. Risk factors for excess mortality and death in adults with tuberculosis in Western Kenya. Int J Tuberc Lung Dis 2012; 16: 1649-1656.
78. Public Health England. Tuberculosis in England 2016 Report. London, UK: PHE, 2016. https://www.gov.uk/government/ uploads/system/uploads/attachment-data/file/492431/TB- Annual-Report-v2.6-07012016.pdf Accessed May 2017.
79. Napoli C, DenteMG, Kärki T, Riccardo F, Rossi P, Declich S. Screening for infectious diseases among newly arrived migrants: experiences and practices in non-EU countries of the Mediterranean Basin and Black Sea. Int J Environ Res Public Health 2015; 12: 15550-15558.
80. Flynn M, Brown L, Tesfai A, Lauer T. Post-migration screening for active tuberculosis in Victoria, Australia. Int J Tuberc Lung Dis 2012; 16: 50-54.
81. Centers for Disease Control and Prevention. Tuberculosis screening and treatment technical instructions (TBTIs) using cultures and directly observed therapy (DOT) for panel physicians. Atlanta, GA, USA: CDC, 2016. http://www.cdc. gov/immigrantrefugeehealth/exams/ti/panel/tuberculosispanel- technical-instructions.html Accessed May 2017.
82. Douglas P, Posey D L, Zenner D, Robson J, Abubakar I, Giovinazzo G. Capacity strengthening through premigration TB screening programmes: IRHWG experiences. Int J Tuberc Lung Dis 2017; 21: 737-745.
83. UK Visas and Immigration. UK tuberculosis technical instructions. September 2013, version 6. London, UK. UK Visas and Immigration, 2013. https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/ 245009/UK-tuberculosis-technical-instructions.pdf Accessed May 2017.
84. Tafuri S, Martinelli D, Melpignano L, et al. Tuberculosis screening in migrant reception centers: results of a 2009 Italian survey. Am J Infect Control 2011; 39: 495-499.
85. Coker R J, Bell A, Pitman R, Hayward A,Watson J. Screening programmes for tuberculosis in new entrants across Europe. Int J Tuberc Lung Dis 2004; 8: 1022-1026.
86. Severi E, Maguire H, Ihekweazu C, Bickler G, Abubakar I. Outcomes analysis of new entrant screening for active tuberculosis in Heathrow and Gatwick airports, United Kingdom 2009/2010. BMC Infect Dis 2016; 16: 178.
87. Aldridge R W, Zenner D, White P J, et al. Prevalence of and risk factors for active tuberculosis in migrants screened before entry to the UK: a population-based cross-sectional study. Lancet Infect Dis 2016; 16: 962-970.
88. Public Health England. UK pre-entry tuberculosis screening report 2015. London, UK: PHE, 2015. https://www.gov.uk/ government/uploads/system/uploads/attachment-data/file/ 555150/UK-pre-entry-tuberculosis-screening-2015- GTW230916.pdf Accessed May 2017.
89. Dasgupta K, Menzies D. Cost-effectiveness of tuberculosis control strategies among immigrants and refugees. Eur Respir J 2005; 25: 1107-1116.
90. Mor Z,Weinstein O, Tischler-Aurkin D, Leventhal A, Alon Y, Grotto I. The yield of tuberculosis screening of undocumented migrants from the Horn of Africa based on chest radiography. Isr Med Assoc J 2015; 17: 11-13.
91. Denholm J T. Immigration screening for latent tuberculosis infection. Med J Aust 2013; 199: 654.
92. Shedrawy J, Siroka A, Oxlade O, Matteelli A, Lönnroth K. Methodological considerations for economic modelling of latent tuberculous infection screening in migrants. Int J Tuberc Lung Dis 2017; 21: 977-989.
93. Fok A, Numata Y, Schulzer M, FitzGerald M J. Risk factors for clustering of tuberculosis cases: a systematic review of population-based molecular epidemiology studies. Int J Tuberc Lung Dis 2008; 12: 480-492.
94. Pai M, Zwerling A, Menzies D. Systematic review: T-cellbased assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149: 177-184.
95. Rangaka M X, Wilkinson K A, Glynn J R, et al. Predictive value of interferon-? release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 45-55.
96. Diel R, Loddenkemper R, Nienhaus A. Predictive value of interferon-c release assays and tuberculin skin testing for progression from latent TB infection to disease state: a metaanalysis. Chest 2012; 142: 63-75.
97. Diel R, Goletti D, Ferrara G, et al. Interferon-c release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J 2011; 37: 88-99.
98. MacIntyre C R, Plant A J. Longitudinal incidence of tuberculosis in South-East Asian refugees after re-settlement. Int J Tuberc Lung Dis 1999; 3: 287-293.
99. Truong D H, Hedemark L L, Mickman J K, Mosher L B, Dietrich S E, Lowry P W. Tuberculosis among Tibetan immigrants from India and Nepal in Minnesota, 1992-1995. JAMA 1997; 277: 735-738.
100. Choudhury I, West C, Ormerod L P. The outcome of a cohort of tuberculin positive predominantly South Asian new entrants aged 16-34 to the United Kingdom: Blackburn 1989-2001. J Public Health (Oxf) 2014; 36: 390-395.
101. Pareek M, Baussano I, Abubakar I, Dye C, Lalvani A. Evaluation of immigrant tuberculosis screening in industrialized countries. Emerg Infect Dis 2012; 18: 1422-1429.
102. Aldridge R W, Zenner D, White P J, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519 955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet 2016; 388: 2510-2518.
103. Smieja M J, Marchetti C A, Cook D J, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000; (2): CD001363.
104. Stagg H R, Zenner D, Harris R J, Muñoz L, Lipman M C, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med 2014; 161: 419-428.
105. Sharma S K, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013; 7: CD007545.
106. Sterling T R, Villarino M E, Borisov A S, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection.N Engl J Med 2011; 365: 2155-2166.
107. Alsdurf H, Hill P C, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and metaanalysis. Lancet Infect Dis 2016; 16: 1269-1278.
108. Sandgren A, Vonk Noordegraaf-Schouten M, van Kessel F, Stuurman A, Oordt-Speets A, van derWerfMJ. Initiation and completion rates for latent tuberculosis infection treatment: a systematic review. BMC Infect Dis 2016; 16: 204.
109. Hirsch-Moverman Y, Daftary A, Franks J, Colson P W. Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada. Int J Tuberc Lung Dis 2008; 12: 1235-1254.
110. Stuurman A L, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets A M, Sandgren A, van der Werf M J. Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review. BMC Infect Dis 2016; 16: 257.
111. Hill A N, Becerra J E, Castro K G. Modelling tuberculosis trends in the USA. Epidemiol Infect 2012; 140: 1862-1872.
112. Houben RMG J,Menzies N A, Sumner T, et al. Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models. Lancet Glob Health 2016; 4: e806- 815.
113. Dye C, Glaziou P, Floyd K, Raviglione M. Prospects for tuberculosis elimination. Annu Rev Public Health 2013; 34: 271-286.
114. Varughese MB, Langlois-Klassen D, Long R, Li M. Preventing tuberculosis in the foreign-born population of Canada: a mathematical modelling study. Int J Tuberc Lung Dis 2014; 18: 405-412.
115. Denholm J T, McBryde E S. Can Australia eliminate TB? Modelling immigration strategies for reachingMDGtargets in a low-transmission setting. Aust NZ J Public Health 2014; 38: 78-82.
116. Linas B P,Wong AY, Freedberg K A, Horsburgh CR. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med 2011; 184: 590-601.
117. Oxlade O, Schwartzman K, Menzies D. Interferon-gamma release assays and TB screening in high-income countries: a cost-effectiveness analysis. Int J Tuberc Lung Dis 2007; 11: 16-26.
118. Auguste P, Tsertsvadze A, Pink J, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technol Assess Winch Engl 2016; 20: 1-678.
119. Campbell J R, Sasitharan T, Marra F. A Systematic review of studies evaluating the cost utility of screening high-risk populations for latent tuberculosis infection. Appl Health Econ Health Policy 2015; 13: 325-340.
120. Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011; 11: 247.
121. Zammarchi L, Casadei G, Strohmeyer M, et al. A scoping review of cost-effectiveness of screening and treatment for latent tubercolosis infection in migrants from high-incidence countries. BMC Health Serv Res 2015; 15: 412.
122. Armstrong R, Hall B J, Doyle J, Waters E. Cochrane Update. 'Scoping the scope' of a Cochrane review. J Public Health 2011; 33: 147-150.